[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364505-105":59,"doc-detail-364505-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prmt3-and-carm1-emerging-epigenetic-targets-in-cancer","PRMT3 and CARM1 - Emerging Epigenetic Targets in Cancer","","Protein arginine methyltransferases (PRMTs) play a central role in cancer initiation and progression. PRMT3 and CARM1, also known as PRMT4, are type I PRMTs that regulate tumour development by catalysing mono-methylation and asymmetric di-methylation of histone and non-histone substrates. This review summarizes their functions and evaluates their value as therapeutic targets across multiple malignancies. Abnormal PRMT3 and CARM1 expression correlates with progression, advancement, and treatment resistance, suggesting new cancer treatment strategies and improved conventional therapy outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prmt3-and-carm1-emerging-epigenetic-targets-in-cancer/364505/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prmt3-and-carm1-emerging-epigenetic-targets-in-cancer/364505.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What roles do PRMT3 and CARM1 play in cancer?","Question",{"text":112,"@type":113},"PRMT3 and CARM1 regulate tumour progression by catalysing mono-methylation and asymmetric di-methylation of histone and non-histone substrates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are PRMTs involved in epigenetics?",{"text":117,"@type":113},"PRMTs participate in protein arginine methylation, a post-translational modification that affects gene-expression-related processes without changing the DNA sequence.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence links PRMT3 and CARM1 to treatment outcomes?",{"text":121,"@type":113},"Abnormal expression of PRMT3 and CARM1 has been identified in multiple malignancies and is closely linked to cancer progression and resistance to treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364505,1790176912,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Journal of Cellular and Molecular Medicine  \nREVIEW  OPEN ACCESS   \nPRMT3 and CARM1: Emerging Epigenetic Targets in Cancer  \nJiezuo Huang1 | Beining Qiao1 | Yixin Yuan2 | Yuxuan Xie3 | Xiaomeng Xia4 | Fenghe Li4  | Lei Wang5  \n1College of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China | 2Xiangya College of Public Health, Central South University, Changsha, China | 3Hunan Normal University School of Medicine, Changsha, China | 4Department of Gynaecology and Obstetrics, Second Xiangya Hospital, Central South University, Changsha, China | 5NHC Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China  \nCorrespondence: Fenghe Li ([lifenghe00@csu.edu.cn](lifenghe00@csu.edu.cn)) | Lei Wang ([leiwang@csu.edu.cn](leiwang@csu.edu.cn))  \nReceived: 11 March 2024 | Revised: 1 January 2025 | Accepted: 15 January 2025  \nFunding: This study was supported by grants from the Natural Science Foundation of Changsha Municipal (No. kq2208312) .  \nKeywords: cancer | CARM1 | epigenetic | inhibitor | PRMT3  \nABSTRACT  \nThe family of protein arginine methyltransferases (PRMTs) occupies an important position in biology, especially during the initiation and development of cancer. PRMT3 and CARM1(also known as PRMT4), being type I protein arginine methyltransferases, are key in controlling tumour progression by catalysing the mono-methylation and asymmetric di-methylation of both histone and non-histone substrates. This paper reviews the functions and potential therapeutic target value of PRMT3 and CARM1 in a variety of cancers. Studies have identified abnormal expressions of PRMT3 and CARM1 in several malignancies, closely linked to cancer progression, advancement, and resistance to treatment. Such as hepatocellular carcinoma, colorectal cancer, ovarian cancer, and endometrial cancer. These findings offer new strategies and directions for cancer treatment, especially in enhancing the effectiveness of conventional treatment methods.  \n1 | Introduction  \nEpigenetics, a mechanism of gene expression regulation that does not involve changes in the DNA sequence, encompasses various processes including DNA methylation and histone modification [1, 2] . Protein arginine methylation stands out in these processes, notably the reactions catalysed by PRMT3 and PRMT4, playing crucial roles in a multitude of physiological and pathological processes [3, 4] . Recent studies indicate that PRMT3 and CARM1 play significant roles in the occurrence and progression of cancer. The protein arginine methylation in which they are involved is an important form of post-translational modification that not only affects protein expression and activity but also participates in processes such as cell signalling,  \nproliferation, apoptosis, and tumour invasion and metastasis. This makes them new potential targets for cancer treatment, offering us new therapeutic strategies.  \nThe family of protein arginine methyltransferases (PRMTs) is ubiquitously present in mammals, becoming a new focal point in epigenetic studies. This family includes several members that influence key processes such as cell growth, differentiation, and proliferation through the catalysis of arginine methylation [5] . Numerous studies have shown the role of PRMTs in cancer, metabolism, neurodegenerative, and muscular diseases [6–11] . Nine members of the PRMT family have been identified in mammals, where PRMTs transfer methyl groups from S-adenosylmethionine to the guanidino nitrogen atoms on the  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecu","cbCair3YYqvXovks","https://ap.wps.com/l/cbCair3YYqvXovks","pdf",3550684,21,"English","# Introduction\n## Epigenetics and protein arginine methylation\n## PRMT family overview and cancer relevance","[{\"question\":\"What roles do PRMT3 and CARM1 play in cancer?\",\"answer\":\"PRMT3 and CARM1 regulate tumour progression by catalysing mono-methylation and asymmetric di-methylation of histone and non-histone substrates.\"},{\"question\":\"How are PRMTs involved in epigenetics?\",\"answer\":\"PRMTs participate in protein arginine methylation, a post-translational modification that affects gene-expression-related processes without changing the DNA sequence.\"},{\"question\":\"What evidence links PRMT3 and CARM1 to treatment outcomes?\",\"answer\":\"Abnormal expression of PRMT3 and CARM1 has been identified in multiple malignancies and is closely linked to cancer progression and resistance to treatment.\"}]","PRMT3 and CARM1 - Emerging Epigenetic Targets in Cancer | PDF",1790157847,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dc53be811fc460dd32656c69c5fec15.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2071f0d0582ac07c67274141567c5fb1.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/385a2d43d05fa143e106bec8e3cd4874.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/203492a2d5042ee91d2ca63f894f6163.webp",980,1287]